Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe gut bugs and sugar link in IBS pain

NCT ID NCT07337707

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at why some people with irritable bowel syndrome (IBS) feel more belly pain after eating fructose (a sugar found in fruit). Researchers will check the gut bacteria and other body signals in 60 IBS patients. No new treatment is tested — the goal is to better understand the connection between fructose, gut microbes, and pain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all groups: * Patients with IBS defined by current Rome criteria (currently IV) * Adult, aged 18 to 75 * Regulatory criteria : * Membership of a social security scheme * Adult having read and understood the information letter and signed the consent form * Woman of childbearing age with effective contraception for the duration of the study such as oestroprogestins, intrauterine device, tubal ligation, vasectomised partner or sexual abstinence (no heterosexual intercourse for 1 month and a negative urine pregnancy test at inclusion). * Postmenopausal women: confirmatory diagnosis (non-medically induced amenorrhoea for at least 12 months prior to the inclusion visit or biologically documented) * Women of childbearing age who have been rendered surgically infertile (e.g. hysterectomy, bilateral salpingectomy, bilateral oophorectomy). For the IBS group with fructose malabsorption and visceral hypersensitivity (named group of interest, MalF-HyperSens) (1): * 25g fructose breath test in favour of fructose malabsorption * Rectal barostat finding visceral hypersensitivity For the IBS group with fructose malabsorption and without visceral hypersensitivity (known as the MalF-NormoSens group) (2): * Fructose breath test at 25g dose in favour of fructose malabsorption * Rectal barostat finding no visceral hypersensitivity For the IBS group without fructose malabsorption and visceral hypersensitivity (named NormoF-HyperSens group) (3): * Fructose breath test at 25g dose in favour of no fructose malabsorption * Rectal barostat finding visceral hypersensitivity For the IBS group without fructose malabsorption or visceral hypersensitivity (called the NormoF-NormoSens group) (4): * Fructose breath test at a dose of 25g in favour of the absence of fructose malabsorption * Rectal barostat finding no visceral hypersensitivity Exclusion Criteria: * Patient who has not undergone a fructose breath test or a barostat in our department in the last 10 years. * Patient with organic digestive pathology (chronic inflammatory bowel disease, microscopic colitis, digestive cancer, celiac disease) * Systemic antibiotic use (oral, IV or IM) in the month prior to inclusion * Regulatory criteria : * Pregnant or parturient or breast-feeding woman or proven absence of contraception, * Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub- guardianship or curatorship, * Person undergoing research participating in another trial / having participated in another trial within a period of 2 weeks, * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol or preventing him/her from giving informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Irritable bowel syndrome (IBS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fructose Intolerance irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU de Rouen

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.